治疗的较佳剂量为每24h皮下注射4.0mg / kg ,持续至少12周。 References 1.Pedersen, N. C., Perron, M., Bannasch, M., Montgomery, E., Murakami, E., Liepnieks, M., & Liu, H. (2019). Efficacy and safety of the nucleoside analog GS-441524 for treatment of cats with naturally occurring...
核苷类似物GS-441524治疗自然发生的猫传染性腹膜炎的有效性和安全性 Efficacy and safety of the nucleoside analog GS-441524 for treatment of cats with naturally occurring feline infectious peritonitis 导…
13 Pedersen NC, Perron M, Bannasch M, et al.Efficacy andsafety of the nucleoside analog GS-441524 for treatmentof cats with naturally occurring feline infectious peritonitis.J Feline Med Surg2019; 21: 271–281. 14 Dickinson PJ, Bannasch M, Thomasy SM, et al.Antiviral treatmentusing the ade...
仿冒的药物441是吉利德的GS441524,它是一款有药效、有专利、但从没上市的药物,也是猫奴都知道的药。...
GS-441524 产品编号T7222别名GS 441524 triphosphateCas号1191237-69-0 GS-441524 是 Remdesivir 的主要活性代谢物,活性更优于 Remdesivir ,治疗患有自然发生的猫传染性腹膜炎的猫。 TargetMol的所有产品仅用作科学研究或药证申报,不能被用于人体,我们不向个人提供产品和服务。请您遵守承诺用途,不得违反法律法规规定...
Remdesivir was never tested in cats (though some vets now offer it[1]), but GS-441524 has been found to be effective treatment for FIP and is widely used despite no official FDA approval due to Gileads refusal to license this drug for veterinary use. GS-441524 manufacturers GS-441524 ...
We determined the pharmacokinetics of GS-441524 in cats in vivo and established a dosage that would sustain effective blood levels for 24 h. In an experimental FIPV infection of cats, GS-441524 treatment caused a rapid reversal of disease signs and return to normality with as little as two...
The effective concentration-50% (EC50) of GS-441524 is calculated to be 0.78 μM [1]. 体内研究 All 10 treated cats have a rapid response to treatment and lymphocyte levels and rectal temperatures return to pre-infection levels and levels of the two asymptomatic cats. Two of the 10 treated...
体内活性: Four of the 31 cats that presented with severe disease died or were euthanized within 2-5 days and a fifth cat after 26 days. The 26 remaining cats completed the planned 12 weeks or more of treatment(GS-441524). Eighteen of these 26 cats remain healthy at the time of publicat...
Remdesivir (RDV, VEKLURY®) is currently the only antiviral therapy fully approved by the FDA for the treatment of COVID-19. The parent nucleoside of RDV, GS-441524, exhibits antiviral activity against numerous respiratory viruses including SARS-CoV-2, although at reduced in vitro potency ...